Evidence map›Paper›PMID 33299547›Full record

Trial reportF1000Research2020

Predicting response and toxicity to PD-1 inhibition using serum autoantibodies identified from immuno-mass spectrometry.

Milena Music, Marco Iafolla, Antoninus Soosaipillai, Ihor Batruch, Ioannis Prassas, Melania Pintilie, Aaron R Hansen, Philippe L Bedard, Stephanie Lheureux, Anna Spreafico and 3 more

Open access · goldAbstract readClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in F1000Research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.5field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 31 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

Milena Music *Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada.
Marco Iafolla *Division of Medical Oncology and Hematology, University Health Network, Canada, Toronto, ON, Canada.
Antoninus SoosaipillaiDepartment of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, Toronto, ON, Canada.
Ihor BatruchDepartment of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, Toronto, ON, Canada.
Ioannis PrassasDepartment of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, Toronto, ON, Canada.ORCID 0000-0002-7907-4576
Melania PintilieDepartment of Biostatistics, Princess Margaret Cancer Centre, University Health Network, Canada, Toronto, ON, Canada.
Aaron R HansenDivision of Medical Oncology and Hematology, University Health Network, Canada, Toronto, ON, Canada.
Philippe L BedardDivision of Medical Oncology and Hematology, University Health Network, Canada, Toronto, ON, Canada.
Stephanie LheureuxDivision of Medical Oncology and Hematology, University Health Network, Canada, Toronto, ON, Canada.
Anna SpreaficoDivision of Medical Oncology and Hematology, University Health Network, Canada, Toronto, ON, Canada.
Albiruni Abdul RazakDivision of Medical Oncology and Hematology, University Health Network, Canada, Toronto, ON, Canada.
Lillian L SiuDivision of Medical Oncology and Hematology, University Health Network, Canada, Toronto, ON, Canada.
Eleftherios P DiamandisDepartment of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada.ORCID 0000-0002-1589-820X
University Health Network · CAMount Sinai Hospital · CAUniversity of Toronto · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AdultAgedAged, 80 and overAntibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalAutoantibodiesBiomarkersFemaleHumansIodide PeroxidaseMaleMass SpectrometryMiddle AgedNeoplasmsProgrammed Cell Death 1 ReceptorThyroglobulinAntibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalAutoantibodiesBiomarkersIodide PeroxidasepembrolizumabProgrammed Cell Death 1 ReceptorThyroglobulinanti-thyroglobulin antibodyanti-thyroid peroxidase antibodyautoantibodieshypothyroidismimmune checkpoint blockadeimmune-related adverse eventspembrolizumabpredictive biomarkersprogrammed cell death protein 1response

Identifiers

PMID33299547
PMCPMC7707117
OpenAlexW3023607046

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.